nach oben

Erschienen in:

01.06.2010 | Original Paper

Autocrine human growth hormone expression leads to resistance of MCF-7 cells to tamoxifen

verfasst von: Majid Mojarrad, Majid Momeny, Fatemeh Mansuri, Yassan Abdolazimi, Mina Hajifaraj Tabrizi, Seyed Hamidollah Ghaffari, Seyed Mohammad Tavangar, Mohammad Hussein Modarressi

Erschienen in: Medical Oncology | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Tamoxifen is the most common antiestrogen used in the treatment of estrogen-positive breast cancer but its adverse effects and also resistance to this drug are serious challenges in the treatment of breast cancer. Characterization of mechanisms responsible for these adverse effects can lead to design of more efficient therapeutic strategies for the treatment of breast cancer. Here, we used a cellular model to evaluate the effects of autocrine expression of human growth hormone on responses of cells to tamoxifen. Our results imply for the first time that autocrine expression of growth hormone in human breast adenocarcinoma cell line, MCF-7, results in increase in cell proliferative capacity of cells even in the presence of tamoxifen. This effect may be due to up-regulation of G-coupled estrogen receptor, GPR30, which is activated by tamoxifen.

Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol. 2000;18:3172–86.PubMed

Katzenellenbogen BS, Montano MM, Ediger TR, Sun J, Ekena K, Lazennec G. Estrogen receptors: selective ligands, partners, and distinctive pharmacology. Recent Prog Horm Res. 2000;55:163–93.PubMed

Early Breast Cancer Trialist’ Collaborative Group (EBCTC). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687–17. doi:10.1016/S0140-6736(05)66544-0.CrossRef

Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell Cycle. 1998;95:927–37.

Funakoshi T, Yanai A, Shinoda K, Kawano MM, Mizukami Y. G protein-coupled receptor 30 is an estrogen receptor in the plasma membrane. Biochem Biophys Res Commun. 2006;346(3):904–10. doi:10.1016/j.bbrc.2006.05.191.CrossRefPubMed

Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Ando S, et al. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol. 2006;20(3):631–46. doi:10.1210/me.2005-0280.CrossRefPubMed

Vivacqua A, Bonofiglio D, Albanito L, Madeo A, Rago V, Carpino A, et al. 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30. Mol Pharmacol. 2006;70(4):1414–23. doi:10.1124/mol.106.026344.CrossRefPubMed

Prossnitz ER, Sklar LA, Oprea TI, Arterburn JB. GPR30: a novel therapeutic target in estrogen-related disease. Trends Pharmacol Sci. 2008;29(3):116–23.PubMed

Matsuda K, Sakamoto H, Mori H, Hosokawa K, Kawamura A, Itose M, et al. Expression and intracellular distribution of the G protein-coupled receptor 30 in rat hippocampal formation. Neurosci Lett. 2008;441(1):94–9. doi:10.1016/j.neulet.2008.05.108.CrossRefPubMed

10.

Wang C, Prossnitz ER, Roy SK. G protein-coupled receptor 30 expression is required for estrogen stimulation of primordial follicle formation in the hamster ovary. Endocrinology. 2008;149(9):4452–61. doi:10.1210/en.2008-0441.CrossRefPubMed

11.

Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science. 2005;307(5715):1625–30. doi:10.1126/science.1106943.CrossRefPubMed

12.

Kleuser B, Malek D, Gust R, Pertz HH, Potteck H. 17-Beta-estradiol inhibits transforming growth factor-beta signaling and function in breast cancer cells via activation of extracellular signal-regulated kinase through the G protein-coupled receptor 30. Mol Pharmacol. 2008;74(6):1533–43. doi:10.1124/mol.108.046854.CrossRefPubMed

13.

Sternlicht M. Key stages in mammary gland development: the cues that regulate ductal branching morphogenesis. Breast Cancer Res. 2006;8(1):201. doi:10.1186/bcr1368.CrossRefPubMed

14.

Kleinberg D. Early mammary development: growth hormone and IGF-1. J Mammary Gland Biol Neoplasia. 1997;2(1):49–57. doi:10.1023/A:1026373513521.CrossRefPubMed

15.

Luft R, Olivecrona H, Sjogren B. Hypophysectomy in man. Nord Med. 1952;47(11):351–4.PubMed

16.

Ray BS, Pearson OH. Hypophysectomy in treatment of disseminated breast cancer. Surg Clin North Am. 1962;42:419–33.PubMed

17.

Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL, et al. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat. 2006;98(3):315–27. doi:10.1007/s10549-006-9168-1.CrossRefPubMed

18.

Mukhina S, Mertani HC, Guo K, Lee KO, Gluckman PD, Lobie PE. Phenotypic conversion of human mammary carcinoma cells by autocrine human growth hormone. Proc Natl Acad Sci USA. 2004;101(42):15166–71. doi:10.1073/pnas.0405881101.CrossRefPubMed

19.

Mertani HC, Garcia-Caballero T, Lambert A, Gérard F, Palayer C, Boutin JM, Vonderhaar BK, Waters MJ, Lobie PE, Morel G. Cellular expression of growth hormone and prolactin receptors in human breast disorders. Int J Cancer. 1998;79(2):202–11. doi:10.1002/(SICI)1097-0215(19980417)79:2<202::AID-IJC17>3.0.CO;2-B.CrossRefPubMed

20.

Antony GJ, Van Wyk JJ, French FS, Weaver RP, Dugger GS, Timmons RL, et al. Influence of pituitary stalk section on growth hormone, insulin and TSH secretion in women with metastatc breast cancer. J Clin Endocrinol Metab. 1969;29(9):1238–50.CrossRefPubMed

21.

Emerman JT, Leahy M, Gout PW, Bruchovsky N. Elevated growth hormone levels in sera from breast cancer patients. Horm Metab Res. 1985;17(8):421–4. doi:10.1055/s-2007-1013563.CrossRefPubMed

22.

Slootweg MC, de Groot RP, Herrmann-Erlee MP, Koornneef I, Kruijer W, Kramer YM. Growth hormone induces expression of c-jun and jun B oncogenes and employs a protein kinase C signal transduction pathway for the induction of c-fos oncogene expression. J Mol Endocrinol. 1991;6(2):179–88. doi:10.1677/jme.0.0060179.CrossRefPubMed

23.

Stoll BA. Growth hormone and breast cancer. Clin Oncol (R Coll Radiol). 1992;4(1):4–5. doi:10.1016/S0936-6555(05)80761-7.

24.

Waters MJ, Conway-Campbell BL. The oncogenic potential of autocrine human growth hormone in breast cancer. Proc Natl Acad Sci USA. 2004;101(42):14992–3. doi:10.1073/pnas.0406396101.CrossRefPubMed

25.

Wagner K, Hemminki K, Israelsson E, Grzybowska E, Klaes R, Chen B, et al. Association of polymorphisms and haplotypes in the human growth hormone 1 (GH1) gene with breast cancer. Endocr Relat Cancer. 2005;12(4):917–28. doi:10.1677/erc.1.01073.CrossRefPubMed

26.

Raccurt M, Lobie PE, Moudilou E, Garcia-Caballero T, Frappart L, Morel G, Mertani HC. High stromal and epithelial human gh gene expression is associated with proliferative disorders of the mammary gland. J Endocrinol. 2002;175: 307–18. doi:10.1677/joe.0.1750307.CrossRefPubMed

27.

Zhu T, Starling-Emerald B, Zhang X, Lee KO, Gluckman PD, Mertani HC, Lobie PE. Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone. Cancer Res. 2005;65(1):317–24.PubMed

28.

Perry JK, Emerald BS, Mertani HC, Lobie PE. The oncogenic potential of growth hormone. Growth Horm IGF Res. 2006;16:277–89. doi:10.1016/j.ghir.2006.09.006.CrossRefPubMed

29.

Perry JK, Mohankumar KM, Emerald BS, Mertani HC, Lobie PE. The contribution of growth hormone to mammary neoplasia. J Mammary Gland Biol Neoplasia. 2008;13:131–45. doi:10.1007/s10911-008-9070-z.CrossRefPubMed

30.

Filardo EJ, Quinn JA, Frackelton AR Jr, Bland KI. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol. 2002;16(1):70–84. doi:10.1210/me.16.1.70.CrossRefPubMed

31.

Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V, et al. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem. 2004;279(26):27008–16. doi:10.1074/jbc.M403588200.CrossRefPubMed

32.

Filardo EJ, Thomas P. GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol Metab. 2005;16(8):362–7. doi:10.1016/j.tem.2005.08.005.CrossRefPubMed

33.

Hsieh YC, Yu HP, Frink M, Suzuki T, Choudhry MA, Schwacha MG, et al. G protein-coupled receptor 30-dependent protein kinase A pathway is critical in nongenomic effects of estrogen in attenuating liver injury after trauma-hemorrhage. Am J Pathol. 2007;170(4):1210–8. doi:10.2353/ajpath.2007.060883.CrossRefPubMed

34.

Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, et al. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res. 2007;67(4):1859–66. doi:10.1158/0008-5472.CAN-06-2909.CrossRefPubMed

35.

Ahmad AM, Hopkins MT, Thomas J, Ibrahim H, Fraser WD, Vora JP. Body composition and quality of life in adults with growth hormone deficiency; effects of low-dose growth hormone replacement. Clin Endocrinol (Oxf). 2001;54(6):709–17. doi:10.1046/j.1365-2265.2001.01275.x.CrossRef

36.

Marino M, Galluzzo P, Ascenzi P. Estrogen signaling multiple pathways to impact gene transcription. Curr Genomics. 2006;7(8):497–508. doi:10.2174/138920206779315737.CrossRefPubMed

37.

Kaganowicz A, Farkouh NH, Frantz AG, Blaustein AU. Ectopic human growth hormone in ovaries and breast cancer. J Clin Endocrinol Metab. 1979;48(1):5–8.CrossRefPubMed

38.

Kaulsay KK, Mertani HC, Törnell J, Morel G, Lee KO, Lobie PE. Autocrine stimulation of human mammary carcinoma cell proliferation by human growth hormone. Exp Cell Res. 1999;250:35–50. doi:10.1006/excr.1999.4492.CrossRefPubMed

39.

Prossnitz ER, Arterburn JB, Sklar LA. GPR30: a G protein-coupled receptor for estrogen. Mol Cell Endocrinol. 2007;265–266:138–42. doi:10.1016/j.mce.2006.12.010.CrossRefPubMed

40.

Filardo EJ. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol. 2002;80(2):231–8. doi:10.1016/S0960-0760(01)00190-X.CrossRefPubMed

41.

Filardo EJ, Quinn JA, Sabo E. Association of the membrane estrogen receptor, GPR30, with breast tumor metastasis and transactivation of the epidermal growth factor receptor. Steroids. 2008;73(9–10):870–3. doi:10.1016/j.steroids.2007.12.025.CrossRefPubMed

42.

Revankar CM, Mitchell HD, Field AS, Burai R, Corona C, Ramesh C, et al. Synthetic estrogen derivatives demonstrate the functionality of intracellular GPR30. ACS Chem Biol. 2007;2(8):536–44. doi:10.1021/cb700072n.CrossRefPubMed

43.

Prossnitz ER, Oprea TI, Sklar LA, Arterburn JB. The ins and outs of GPR30: a transmembrane estrogen receptor. J Steroid Biochem Mol Biol. 2008;109(3–5):350–3. doi:10.1016/j.jsbmb.2008.03.006.CrossRefPubMed

44.

Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol. 2000;14(10):1649–60. doi:10.1210/me.14.10.1649.CrossRefPubMed

45.

Albanito L, Sisci D, Aquila S, Brunelli E, Vivacqua A, Madeo A, et al. Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells. Endocrinology. 2008;149(8):3799–808. doi:10.1210/en.2008-0117.CrossRefPubMed

46.

Zhang Z, Duan L, Du X, Ma H, Park I, Lee C, et al. The proliferative effect of estradiol on human prostate stromal cells is mediated through activation of ERK. Prostate. 2008;68(5):508–16. doi:10.1002/pros.20722.CrossRefPubMed

47.

Kanda N, Watanabe S. 17beta-estradiol stimulates the growth of human keratinocytes by inducing cyclin D2 expression. J Invest Dermatol. 2004;123(2):319–28. doi:10.1111/j.0022-202X.2004.12645.x.CrossRefPubMed

48.

Kamanga-Sollo E, White ME, Chung KY, Johnson BJ, Dayton WR. Potential role of G-protein-coupled receptor 30 (GPR30) in estradiol-17beta-stimulated IGF-I mRNA expression in bovine satellite cell cultures. Domest Anim Endocrinol. 2008;35(3):254–62. doi:10.1016/j.domaniend.2008.06.001.CrossRefPubMed

49.

Sirianni R, Chimento A, Ruggiero C, De Luca A, Lappano R, Ando S, et al. The novel estrogen receptor, G protein-coupled receptor 30, mediates the proliferative effects induced by 17beta-estradiol on mouse spermatogonial GC-1 cell line. Endocrinology. 2008;149(10):5043–51. doi:10.1210/en.2007-1593.CrossRefPubMed

50.

Prakash Pandey D, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D. Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J. 2009;28:523–32.CrossRef

51.

Zujewski J. Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention. Environ Mol Mutagen. 2002;39:264–70.CrossRefPubMed

52.

Roy RN, Gerulath AH, Cecutti A, Bhavani BR. Effect of tamoxifen treatment on the endometrial expression of human insulin-like growth factors and their receptor mRNAs. Mol Cell Endocrinol. 2000;165:173–8. doi:10.1016/S0303-7207(00)00248-3.CrossRefPubMed

53.

Lobie PE, García-Aragón J, Wang BS, Baumbach WR, Waters MJ. Cellular localization of the growth hormone receptor/binding proteins in the male and female reproductive systems. Endocrinology. 1990;126:2214–21.CrossRefPubMed

Titel: Autocrine human growth hormone expression leads to resistance of MCF-7 cells to tamoxifen
verfasst von: Majid Mojarrad
Majid Momeny
Fatemeh Mansuri
Yassan Abdolazimi
Mina Hajifaraj Tabrizi
Seyed Hamidollah Ghaffari
Seyed Mohammad Tavangar
Mohammad Hussein Modarressi
Publikationsdatum: 01.06.2010
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 2/2010
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-009-9237-5

Springer Medizin

Autocrine human growth hormone expression leads to resistance of MCF-7 cells to tamoxifen

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2010

Identification of human gastric carcinoma biomarkers by differential protein expression analysis using 18O labeling and NanoLC-MS/MS coupled with laser capture microdissection

Neoadjuvant chemotherapy for “Triple Negative” breast cancer: a review of current practice and future outlook

GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population

Letter to the editor

Intensive chemotherapy failure in Burkitt’s lymphoma with cavernous sinus involvement

Analysis of a case with disappearance of the primary gastrointestinal stromal tumor and progressive liver metastases under long-term treatment with tyrosine kinase inhibitors

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie